Barclays Upgrades AbbVie to Overweight, Raises Price Target to $170
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould has upgraded AbbVie (NYSE:ABBV) from Equal-Weight to Overweight and raised the price target from $160 to $170.
October 30, 2023 | 10:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's stock has been upgraded to Overweight by Barclays, with a raised price target of $170.
The upgrade from Barclays indicates a positive outlook for AbbVie. The raised price target suggests that the analyst believes the stock is undervalued at its current price, which could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100